摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H-吲哚-5-甲腈,1-(4-氟苯基)-3-[1,2,3,6-四氢-1-[2-(2-羰基-1-咪唑烷基)乙基]-4-吡啶基]- | 138900-26-2

中文名称
1H-吲哚-5-甲腈,1-(4-氟苯基)-3-[1,2,3,6-四氢-1-[2-(2-羰基-1-咪唑烷基)乙基]-4-吡啶基]-
中文别名
——
英文名称
1-(2-{4-[5-cyano-1-(4-fluorophenyl)-1H-indol-3-yl]-1,2,3,6-tetrahydropyridin-1-yl}ethyl)-2-imidazolidinone
英文别名
1-(4-Fluoro-phenyl)-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1H-indole-5-carbonitrile;1-(4-fluorophenyl)-3-[1-[2-(2-oxoimidazolidin-1-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl]indole-5-carbonitrile
1H-吲哚-5-甲腈,1-(4-氟苯基)-3-[1,2,3,6-四氢-1-[2-(2-羰基-1-咪唑烷基)乙基]-4-吡啶基]-化学式
CAS
138900-26-2
化学式
C25H24FN5O
mdl
——
分子量
429.497
InChiKey
XIIDUDUKMUCPBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    32
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    64.3
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1H-吲哚-5-甲腈,1-(4-氟苯基)-3-[1,2,3,6-四氢-1-[2-(2-羰基-1-咪唑烷基)乙基]-4-吡啶基]-platinum(IV) oxide 氢气三乙胺 作用下, 以 二氯甲烷溶剂黄146 为溶剂, 20.0 ℃ 、294.18 kPa 条件下, 反应 5.0h, 生成 N-(1-(4-Fluoro-phenyl)-3-{1-[2-(2-oxo-imidazolidin-1-yl)-ethyl]-piperidin-4-yl}-1H-indol-5-ylmethyl)-acetamide
    参考文献:
    名称:
    抗精神病药sertindole的5-氨基甲基和5-氨基甲酰基类似物的合成及结构亲和关系研究。一类新的选择性α1肾上腺素受体拮抗剂。
    摘要:
    描述了一种新型的选择性α(1)肾上腺素能受体拮抗剂,其源自抗精神病药塞多度。最有效和选择性最大的化合物1-(2-(4- [5-氨基甲基-1-(4-氟苯基)-1H-吲哚-3-基] -1-哌啶基)乙基)-2-咪唑啉酮(11)结合对α(1)肾上腺素受体具有0.50 nM的亲和力,对多巴胺D(2),D(3),D(4)和5-羟色胺5-HT(1A),5-HT(1B)的亲和力低44倍以上,5-HT(2A)和5-HT(2C)受体。讨论了为肾上腺素α(1)受体提供高亲和力和对多巴胺D(2)和5-羟色胺5-HT(2A)和5-HT(2C)受体的高选择性的分子特征。
    DOI:
    10.1016/s0968-0896(02)00459-5
  • 作为产物:
    描述:
    1-(2-氯乙基)-2-咪唑啉酮 、 1-(4-Fluoro-phenyl)-3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole-5-carbonitrile 在 potassium carbonate 、 potassium iodide 作用下, 以 various solvent(s) 为溶剂, 反应 16.0h, 生成 1H-吲哚-5-甲腈,1-(4-氟苯基)-3-[1,2,3,6-四氢-1-[2-(2-羰基-1-咪唑烷基)乙基]-4-吡啶基]-
    参考文献:
    名称:
    一系列3-取代的1-(4-氟苯基)-1H-吲哚类化合物中的非致死因,中枢性多巴胺D-2和5-羟色胺5-HT2拮抗剂。
    摘要:
    合成了一系列在3-位被1-哌嗪基,1,2,3,6-四氢-4-吡啶基和4-哌啶基取代的1-(4-氟苯基)-1H-吲哚。在所有三个亚系列中,在配体结合研究中发现了有效的多巴胺D-2和5-羟色胺5-HT2受体亲和力。作为对中枢5-HT 2受体拮抗作用的量度,大多数衍生物抑制了奎帕嗪诱导的大鼠头部抽搐。哌嗪基和四氢吡啶基吲哚是致肽原的,而哌啶基取代的吲哚令人惊讶地被发现是非致肽原的或仅是弱致肽原的。非致死因的哌啶基衍生物也未能阻止多巴胺能介导的定型观念,即哌醋甲酯诱导的小鼠行为。这些特征类似于非典型的精神抑制药氯氮平的特征。为了避免僵直,发现1-乙基-2-咪唑啉酮是碱性氮原子的最佳取代基。非典型的抗精神病药1- [2- [4- [5-氯-1-(4-氟苯基)-1H-吲哚-3-基] -1-哌啶基]乙基] -2-咪唑啉酮(sertindole,化合物14c)为这些结构/活性研究的结果,选择了进一步开发。
    DOI:
    10.1021/jm00084a014
点击查看最新优质反应信息

文献信息

  • 5-aminoalkyl and 5-aminocarbonyl substituted indoles
    申请人:H. Lundbeck A/S
    公开号:US20020169169A1
    公开(公告)日:2002-11-14
    1 The present invention relates to 5-aminoalkyl and 5-aminocarbonyl substituted indole derivatives having formula (1), wherein R 1 is-(CH 2 ) n-1 -CONR 10 R 11 , -(CH 2 ) n -CONR 10 R 11 or (a), wherein R 10 and R 11 independently are selected from substituents defined herein; n is 1 to 3 and q is 2 to 5; G is N, C, or CH; Ar is phenyl optionally substituted with one or more substituents, or Ar is heterocyclic; R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from substituents defined herein; m is an integer from 2-6; W is O or S; U is N or CH; Z is —(CH 2 ) p -, p being 2 or 3, or Z is —CH═CH—or 1 ,2-phenylene, or Z is—COCH 2 - or —CSCH 2 -; V is O, S, CH 2 , or NR 9 ; X is N, C, or CH; Y is N, C, or CH; provided at least one of X and Y is N; or a pharmaceutically acceptable acid addition salt thereof. The novel 5-substituted indoles have high affinity for &agr; 1 -adrenoceptors and are considered useful for the treatment of diseases or disorders responsive to &agr; 1 -adrenoceptor antagonists. Further, as the compounds are selective &agr; 1 -adrenoceptor ligands they may be particularly useflul as PET or SPECT ligands.
    本发明涉及具有公式(1)的5-氨基烷基和5-氨基羰基取代的吲哚衍生物,其中R1是-(CH2)n-1-CONR10R11,-(CH2)n-CONR10R11或(a),其中R10和R11独立地选择自此处定义的取代基;n为1至3,q为2至5;G为N、C或CH;Ar为苯基,可以选择一个或多个取代基进行取代,或Ar为杂环基;R2、R3、R4、R5和R6独立地选择自此处定义的取代基;m是2-6的整数;W为O或S;U为N或CH;Z为-(CH2)p-,其中p为2或3,或Z为-CH=CH-或1,2-苯基,或Z为-COCH2-或-CSCH2-;V为O、S、CH2或NR9;X为N、C或CH;Y为N、C或CH;其中至少一个为N;或其药学可接受的酸加合物。这些新型的5-取代吲哚具有高亲和力的α1-肾上腺素受体,被认为对于对α1-肾上腺素受体拮抗剂有反应的疾病或疾病的治疗有用。此外,由于这些化合物是选择性的α1-肾上腺素受体配体,它们可能特别有用作PET或SPECT配体。
  • 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES
    申请人:H. LUNDBECK A/S
    公开号:EP1214312B1
    公开(公告)日:2004-04-14
  • US6833376B2
    申请人:——
    公开号:US6833376B2
    公开(公告)日:2004-12-21
  • [EN] 5-AMINOALKYL AND 5-AMINOCARBONYL SUBSTITUTED INDOLES<br/>[FR] INDOLES SUBSTITUES 5-AMINOALKYLE ET 5-AMINOCARBONYLE
    申请人:LUNDBECK & CO AS H
    公开号:WO2001021614A1
    公开(公告)日:2001-03-29
    The present invention relates to 5-aminoalkyl and 5-aminocarbonyl substituted indole derivatives having general formula (I), wherein R1 is-(CH¿2?)n-1-CONR?10R11¿, -(CH¿2?)n-NR?10R11¿ or (a), wherein R?10 and R11¿ independently are selected from hydrogen, C¿1-6?-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-8-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, aryl-C1-6-alkyl, aryl, acyl, amino-C1-6-alkyl and mono- or di-C1-6-alkylamino-C1-6-alkyl, R?12¿ is hydrogen, or C¿1-6?-alkyl n is 1 to 3 and q is 2 to 5; G is N, C, or CH; the dotted line meaning a bond when G is C, and the dotted line meaning no bond when G is CH, or N; Ar is phenyl optionally substituted with one or more substituents independently selected from halogen, C1-6-alkyl, C1-6-alkoxy, hydroxy, trifluoromethyl and cyano, or Ar is 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; R?2, R3, R4 and R5¿ are independently selected from hydrogen, C¿1-6?-alkyl, C1-6-alkoxy, hydroxy, halogen, trifluoromethyl, nitro, cyano, amino, C1-6-alkylamino and C1-6-dialkylamino; R?6¿ is hydrogen, or C¿3-8?-cycloalkyl, C3-8-cycloalkyl-C1-6-alkyl, C1-6-alkyl, C2-6-alkenyl or C2-6-alkenyl, which may optionally be substituted with one or two hydroxy groups, any hydroxy group present being optionally esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms inclusive, or R?6¿ is a group of Formula (II) or (III): wherein m is an integer from 2-6; W is O, or S; U is N or CH; Z is -(CH¿2?)p-, p being 2 or 3, or Z is -CH=CH- or 1,2-phenylene optionally substituted with halogen or trifluoromethyl, or Z is -COCH2- or -CSCH2-; V is O, S, CH2, or NR?9¿ wherein R9 is hydrogen, or C¿1-6?-alkyl, C2-6-alkenyl or C2-6-alkenyl, which may optionally be substituted with one or two hydroxy groups, or a C3-8-cycloalkyl or C3-8-cycloalkyl-C1-6-alkyl group; X is N, C, or CH; Y is N, C, or CH; provided at least one of X and Y is N; and R?7¿ is hydrogen, or C¿1-6?-alkyl; or a pharmaceutically acceptable acid addition salt thereof. The novel 5-aminoalkyl and 5-aminocarbonyl substituted indoles have high affinity for α1-adrenoceptors and are considered useful for the treatment of diseases or disorders responsive to α1-adrenoceptor antagonists. Further, as the compounds are selective α1-adrenoceptor ligands they may be particularly useful as PET or SPECT ligands.
  • Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles
    作者:Jens Perregaard、Joern Arnt、Klaus P. Boegesoe、John Hyttel、Connie Sanchez
    DOI:10.1021/jm00084a014
    日期:1992.3
    antagonism. Piperazinyl and tetrahydropyridyl indoles were cataleptogenic, while piperidyl substituted indoles surprisingly were found to be noncataleptogenic or only weakly cataleptogenic. Noncataleptogenic piperidyl derivatives also failed to block dopaminergic-mediated stereotypies, that is methyl phenidate-induced gnawing behavior in mice. These profiles resemble that of the atypical neuroleptic clozapine
    合成了一系列在3-位被1-哌嗪基,1,2,3,6-四氢-4-吡啶基和4-哌啶基取代的1-(4-氟苯基)-1H-吲哚。在所有三个亚系列中,在配体结合研究中发现了有效的多巴胺D-2和5-羟色胺5-HT2受体亲和力。作为对中枢5-HT 2受体拮抗作用的量度,大多数衍生物抑制了奎帕嗪诱导的大鼠头部抽搐。哌嗪基和四氢吡啶基吲哚是致肽原的,而哌啶基取代的吲哚令人惊讶地被发现是非致肽原的或仅是弱致肽原的。非致死因的哌啶基衍生物也未能阻止多巴胺能介导的定型观念,即哌醋甲酯诱导的小鼠行为。这些特征类似于非典型的精神抑制药氯氮平的特征。为了避免僵直,发现1-乙基-2-咪唑啉酮是碱性氮原子的最佳取代基。非典型的抗精神病药1- [2- [4- [5-氯-1-(4-氟苯基)-1H-吲哚-3-基] -1-哌啶基]乙基] -2-咪唑啉酮(sertindole,化合物14c)为这些结构/活性研究的结果,选择了进一步开发。
查看更多